Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.

Cancer immunotherapy: novel strategies and clinical experiences.

Schmitz M, Bornhäuser M, Ockert D, Rieber EP.

Trends Immunol. 2002 Sep;23(9):428-9. No abstract available.

PMID:
12200057
2.
3.

T cell responses against mutant ras: a basis for novel cancer vaccines.

Gaudernack G.

Immunotechnology. 1996 Feb;2(1):3-9. Review. No abstract available.

PMID:
9373323
4.

Dendritic cells in tumor immunology and immunotherapy.

Turtle CJ, Hart DN.

Curr Drug Targets. 2004 Jan;5(1):17-39. Review.

PMID:
14738216
5.

Immunotherapy of cancer through targeting of minor histocompatibility antigens.

Hambach L, Goulmy E.

Curr Opin Immunol. 2005 Apr;17(2):202-10. Review.

PMID:
15766682
6.

Dendritic cell-based cancer immunotherapy.

Engleman EG.

Semin Oncol. 2003 Jun;30(3 Suppl 8):23-9. Review.

PMID:
12881809
7.

Dendritic cell immunotherapy for the treatment of neoplastic disease.

Decker WK, Xing D, Shpall EJ.

Biol Blood Marrow Transplant. 2006 Feb;12(2):113-25. Review.

8.

Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides.

Hsu DH, Paz P, Villaflor G, Rivas A, Mehta-Damani A, Angevin E, Zitvogel L, Le Pecq JB.

J Immunother. 2003 Sep-Oct;26(5):440-50.

PMID:
12973033
9.

Dendritic cell-tumor cell hybrids and immunotherapy: what's next?

Cathelin D, Nicolas A, Bouchot A, Fraszczak J, Labbé J, Bonnotte B.

Cytotherapy. 2011 Aug;13(7):774-85. doi: 10.3109/14653249.2011.553593. Epub 2011 Feb 7.

PMID:
21299362
10.

Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy.

Bonehill A, Heirman C, Thielemans K.

J Gene Med. 2005 Jun;7(6):686-95. Review.

PMID:
15693037
11.

Antitumor activity of syngeneic/autologous graft-versus-host disease.

Hess AD, Kennedy MJ, Ruvolo PP, Vogelsang GB, Jones RJ.

Ann N Y Acad Sci. 1995 Dec 29;770:189-202. Review. No abstract available.

PMID:
8597360
12.

Dendritic cell immunotherapy: mapping the way.

Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ.

Nat Med. 2004 May;10(5):475-80. Review.

PMID:
15122249
13.

Dendritic cells as vectors for immunotherapy of cancer.

Paczesny S, Ueno H, Fay J, Banchereau J, Palucka AK.

Semin Cancer Biol. 2003 Dec;13(6):439-47. Review.

PMID:
15001163
14.

DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy.

Schultze JL, Grabbe S, von Bergwelt-Baildon MS.

Trends Immunol. 2004 Dec;25(12):659-64. Review.

PMID:
15530836
15.
16.

Cancer immunotherapy: will expanding knowledge lead to success in pediatric oncology?

Fry TJ, Lankester AC.

Pediatr Clin North Am. 2008 Feb;55(1):147-67, xi. doi: 10.1016/j.pcl.2007.10.015. Review.

PMID:
18242319
17.

Cancer immunotherapy targeting the telomerase reverse transcriptase.

Huo LF, Tang JW, Huang JJ, Huang PT, Huang CF, Kung HF, Lin MC.

Cell Mol Immunol. 2006 Feb;3(1):1-11. Review.

18.

Minors come of age: Minor histocompatibility antigens and graft-versus-host disease.

Chao NJ.

Biol Blood Marrow Transplant. 2004 Apr;10(4):215-23. Review.

19.

Dendritic cell-based vaccines and therapies for cancer.

Tatsumi T, Storkus WJ.

Expert Opin Biol Ther. 2002 Dec;2(8):919-28. Review.

PMID:
12517270
20.

Cell fusion: from hybridoma to dendritic cell-based vaccine.

Gong J, Koido S, Calderwood SK.

Expert Rev Vaccines. 2008 Sep;7(7):1055-68. doi: 10.1586/14760584.7.7.1055. Review.

PMID:
18767954

Supplemental Content

Support Center